Kventiax

Quetiapine, the active ingredient in Kventiax, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the management of schizophrenia, bipolar disorder and as adjunct therapy in major depressive disorder, primarily in adult patients. GNH USA supplies Kventiax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. Our network ensures timely delivery and regulatory compliance across regions.

Quetiapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric conditions. - Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Bipolar disorder: stabilises mood, decreasing manic and depressive episodes. - Major depressive disorder (adjunct): enhances antidepressant response when added to standard therapy.

Common side effects are generally mild to moderate and may resolve with continued therapy.

Common Side Effects: - Sedation or somnolence - Dizziness or light‑headedness - Dry mouth - Constipation - Weight gain - Orthostatic hypotension

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis or severe leukopenia - Significant cardiac arrhythmias - Suicidal thoughts or behavior - Severe hypotension or syncope - Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should evaluate several safety parameters. - Monitor blood pressure: watch for orthostatic changes, especially at treatment start. - Assess metabolic profile: track weight, glucose and lipid levels regularly. - Evaluate for suicidal ideation: particularly in depressive or bipolar patients. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper to minimise withdrawal or relapse. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Quetiapine may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase quetiapine levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce quetiapine exposure. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression. - Antihypertensive agents: risk of excessive hypotension. - Anticholinergic drugs: may worsen cognitive side effects.

Moderate Interactions (Monitor Closely): - Other antipsychotics: cumulative dopamine blockade. - SSRIs or SNRIs: potential serotonin syndrome. - Lithium: monitor serum levels for neurotoxicity. - Antihistamines: increased sedation. - QT‑prolonging agents: monitor cardiac rhythm.